{"id":78754,"date":"2026-09-04T15:57:10","date_gmt":"2026-09-04T07:57:10","guid":{"rendered":"https:\/\/flcube.com\/?p=78754"},"modified":"2026-09-04T15:57:11","modified_gmt":"2026-09-04T07:57:11","slug":"genscript-proposes-probio-spin-off-for-standalone-listing-on-hkex-main-board","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78754","title":{"rendered":"GenScript Proposes ProBio Spin-Off for Standalone Listing on HKEX Main Board"},"content":{"rendered":"\n

Genscript Biotech Corporation (HKG: 1548<\/a>)<\/strong> announced that it proposes to spin off its indirect non-wholly-owned subsidiary, Probio Technology Limited (“ProBio”)<\/strong>, and separately list its shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX)<\/strong>. The move would unlock a standalone listing for GenScript\u2019s<\/strong> Biologics and Advanced Therapy CDMO<\/strong> business, following the Listing Committee\u2019s<\/strong> confirmation on 14 August 2026<\/strong> that the company may proceed with the proposed spin-off under Practice Note 15 of the Listing Rules.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Parent Company<\/td>Genscript Biotech Corporation (HKG: 1548)<\/strong><\/td><\/tr>
Spin-Off Entity<\/td>Probio Technology Limited (“ProBio”)<\/strong>, an indirect non-wholly-owned subsidiary<\/td><\/tr>
Listing Venue<\/td>Main Board of The Stock Exchange of Hong Kong Limited (HKEX)<\/strong><\/td><\/tr>
Regulatory Basis<\/td>Application submitted in compliance with Practice Note 15<\/strong> of the Listing Rules<\/td><\/tr>
Key Milestone<\/td>14 Aug 2026 \u2013 Listing Committee<\/strong> confirmed GenScript may proceed with the Proposed Spin-off<\/td><\/tr>
Next Steps<\/td>Preparation and submission of the listing application for ProBio on the HKEX Main Board<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Business Profile: ProBio<\/h2>\n\n\n\n